FFCP PHASE1:Mm9::chr18:36868860..36868878,+: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{{FFCP|EntrezGene=NA|HGNC=|MCL_coexpression_id=6|UniProt=NA|association_with_transcript=NA|description=CAGE_peak_at_chr18:36868860..36868878,+|id=chr18:36868860..36868878,+|ontology_enrichment_celltype=CL:0000988!4.99e-10!32;CL:0002032!4.99e-10!32;CL:0000037!4.99e-10!32;CL:0000566!4.99e-10!32;CL:0000837!4.99e-10!32;CL:0000049!3.92e-09!19;CL:0000557!4.77e-09!7;CL:0000034!4.17e-08!97;CL:0002320!6.85e-08!46;CL:0000134!6.85e-08!46;CL:0000144!8.65e-07!121;CL:0000012!8.65e-07!121|ontology_enrichment_celltype_v019_2=CL:0000049,1.58e-13,19;CL:0000557,7.54e-13,7;CL:0000988,8.92e-08,32;CL:0002032,8.92e-08,32;CL:0000037,8.92e-08,32;CL:0000837,8.92e-08,32|ontology_enrichment_disease=DOID:0060100!8.08e-13!3;DOID:4045!8.08e-13!3|ontology_enrichment_disease_v019_2=DOID:0060100,5.55e-18,3;DOID:4045,5.55e-18,3;DOID:0050686,2.90e-09,6|ontology_enrichment_uberon=UBERON:0002384!6.85e-08!46|ontology_enrichment_uberon_v019_2=UBERON:0002204,5.45e-08,32|phase1_expression=0,0,0,0,0,0,0,0,0.281577444303333,0,0,0,0,0,0,0,0,0,0,0,0,0.0992909512008853,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12.1374172913703,12.5013655123808,5.75876118371178,34.7056577938298,15.0270006690858,6.311634589405,0,0,0,0,0,0,0,0,0,0,0,0.336093799142464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.579728977403356,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1.01104889002957,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3.11519323715393,2.39961092397363,3.55796635804581,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.175951124163949,0,0,0,0,0,4.21327912387941,2.83082697826187,3.6941254921427,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.162135226775035,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.163863314715738,0,0,3.01582567878545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1.18984900995699,1.39951452323658,0.690999869022119,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0|short_description=p@chr18:36868860..36868878,+}} | {{FFCP | ||
|DHSsupport=NA | |||
|DPIdataset=NA | |||
|EntrezGene=NA | |||
|HGNC= | |||
|MCL_coexpression_id=6 | |||
|TSSclassifier=NA | |||
|UniProt=NA | |||
|association_with_transcript=NA | |||
|cluster_id=chr18:36868860..36868878,+ | |||
|description=CAGE_peak_at_chr18:36868860..36868878,+ | |||
|id=chr18:36868860..36868878,+ | |||
|ontology_enrichment_celltype=CL:0000988!4.99e-10!32;CL:0002032!4.99e-10!32;CL:0000037!4.99e-10!32;CL:0000566!4.99e-10!32;CL:0000837!4.99e-10!32;CL:0000049!3.92e-09!19;CL:0000557!4.77e-09!7;CL:0000034!4.17e-08!97;CL:0002320!6.85e-08!46;CL:0000134!6.85e-08!46;CL:0000144!8.65e-07!121;CL:0000012!8.65e-07!121 | |||
|ontology_enrichment_celltype_v019_2=CL:0000049,1.58e-13,19;CL:0000557,7.54e-13,7;CL:0000988,8.92e-08,32;CL:0002032,8.92e-08,32;CL:0000037,8.92e-08,32;CL:0000837,8.92e-08,32 | |||
|ontology_enrichment_disease=DOID:0060100!8.08e-13!3;DOID:4045!8.08e-13!3 | |||
|ontology_enrichment_disease_v019_2=DOID:0060100,5.55e-18,3;DOID:4045,5.55e-18,3;DOID:0050686,2.90e-09,6 | |||
|ontology_enrichment_uberon=UBERON:0002384!6.85e-08!46 | |||
|ontology_enrichment_uberon_v019_2=UBERON:0002204,5.45e-08,32 | |||
|phase1_expression=0,0,0,0,0,0,0,0,0.281577444303333,0,0,0,0,0,0,0,0,0,0,0,0,0.0992909512008853,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,12.1374172913703,12.5013655123808,5.75876118371178,34.7056577938298,15.0270006690858,6.311634589405,0,0,0,0,0,0,0,0,0,0,0,0.336093799142464,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.579728977403356,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1.01104889002957,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3.11519323715393,2.39961092397363,3.55796635804581,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.175951124163949,0,0,0,0,0,4.21327912387941,2.83082697826187,3.6941254921427,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.162135226775035,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.163863314715738,0,0,3.01582567878545,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1.18984900995699,1.39951452323658,0.690999869022119,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0 | |||
|short_description=p@chr18:36868860..36868878,+ | |||
}} |
Latest revision as of 17:30, 5 August 2015
Short description: | p@chr18:36868860..36868878, + |
---|---|
Species: | Mouse (Mus musculus) |
DPI dataset: | NA |
TSS-like-by-RIKEN-classifier(Yes/No): | NA |
DHS support(Yes/No): | NA |
Description: | CAGE_peak_at_chr18:36868860..36868878, + |
Coexpression cluster: | MCL_coexpression_mm9:6 |
Association with transcript: | NA |
EntrezGene: | NA |
Link to Zenbu: | ZENBU |
View on UCSC genome browser
CAGE Expression
- Click each plot point to find sample in table
Ontology-based sample term enrichment analysis<b>Summary:</b>This analysis has been performed by utilizing wilcoxon rank sum test.When the number of associated cells/tissues are > n , randomly sampled n cells/tissues are used for P value calculation with rank sum test. this process are repeated several times, and the P values are averaged on the log space <br><b>Analyst:</b> Hideya Kawaji<br><br>link to source dataset<br>data
Ontology term | p-value | n |
---|---|---|
common myeloid progenitor | 1.58e-13 | 19 |
granulocyte monocyte progenitor cell | 7.54e-13 | 7 |
hematopoietic cell | 8.92e-08 | 32 |
hematopoietic oligopotent progenitor cell | 8.92e-08 | 32 |
hematopoietic stem cell | 8.92e-08 | 32 |
hematopoietic multipotent progenitor cell | 8.92e-08 | 32 |
Ontology term | p-value | n |
---|---|---|
musculoskeletal system | 5.45e-08 | 32 |
Ontology term | p-value | n |
---|---|---|
musculoskeletal system cancer | 5.55e-18 | 3 |
muscle cancer | 5.55e-18 | 3 |
organ system cancer | 2.90e-09 | 6 |